CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL
Services-Commercial Physical & Biological Research · NYSE
Ingresos
$4.13B
+3.9% A/A
Ingresos netos
$474.62M
-2.4% A/A
Activos totales
$7.53B
-8.1% A/A
EPS
9.22
-2.7% A/A
Advertisement
Estado de ingresos
| Período | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Revenues | $2.02B | $984.17M | $4.13B | $3.05B | $2.04B | $1.01B | $3.98B | $3.12B |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| SG&A Expense | $369.35M | $177.80M | $747.86M | $555.29M | $356.08M | $186.29M | $665.10M | $550.71M |
| Operating Income (Loss) | $174.80M | $74.67M | $617.26M | $395.03M | $277.63M | $125.98M | $650.98M | $484.34M |
| Interest Expense | — | — | — | — | — | — | — | — |
| Net Income (Loss) | $77.80M | $25.47M | $474.62M | $236.70M | $167.04M | $72.96M | $486.23M | $287.54M |
| EPS (Diluted) | 1.55 | 0.50 | 9.22 | 4.37 | 3.04 | 1.30 | 9.48 | 5.58 |
Balance general
| Período | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.14B | $7.14B | $7.53B | $7.53B | $7.53B | $7.53B | $8.20B | $8.20B |
| Current Assets | $1.45B | $1.45B | $1.40B | $1.40B | $1.40B | $1.40B | $1.61B | $1.61B |
| Cash & Equivalents | $182.82M | $229.36M | $194.61M | $210.17M | $179.21M | $327.04M | $276.77M | $157.17M |
| Accounts Receivable | $708.86M | $708.86M | $720.91M | $720.91M | $720.91M | $720.91M | $780.38M | $780.38M |
| Inventory | $299.10M | $299.10M | $278.54M | $278.54M | $278.54M | $278.54M | $380.26M | $380.26M |
| PP&E (Net) | $1.66B | $1.66B | $1.60B | $1.60B | $1.60B | $1.60B | $1.64B | — |
| Goodwill | $2.76B | $2.76B | $2.85B | $2.85B | $2.85B | $2.85B | $3.10B | $3.10B |
| Total Liabilities | $3.92B | $3.92B | $4.02B | $4.02B | $4.02B | $4.02B | $4.54B | $4.54B |
| Current Liabilities | $1.12B | $1.12B | $994.10M | $994.10M | $994.10M | $994.10M | $1.06B | $1.06B |
| Accounts Payable | $148.80M | $148.80M | $140.34M | $140.34M | $140.34M | $140.34M | $168.94M | $168.94M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Stockholders Equity | $3.16B | $3.16B | $3.46B | $3.46B | $3.46B | $3.46B | $3.60B | $3.60B |
Estado de flujo de efectivo
| Período | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $376.30M | $171.70M | $683.90M | $575.22M | $323.42M | $129.89M | $619.64M | $462.95M |
| Investing Cash Flow | $-82.82M | $-45.48M | $-563.15M | $-168.98M | $-147.66M | $-85.79M | $-607.92M | $-324.78M |
| Financing Cash Flow | $-332.25M | $-105.33M | $-85.52M | $-475.05M | $-267.51M | $18.35M | $-42.40M | $-209.09M |
| Stock Repurchases | $360.48M | $353.13M | $24.16M | $119.05M | $18.27M | $9.35M | $38.65M | $24.02M |
Empresas similares
Aprende más
How to Find Any SEC Filing in Two MinutesCash-Flow Quality: Profit Is an Opinion, Cash Is a FactValuation Basics: P/E, P/S and What They Actually Tell YouDividends: How Companies Pay Shareholders and How to Read ThemHow to Read a 10-K Annual Report (Without Falling Asleep)Understanding Earnings Per Share (EPS)How to Read a Cash Flow StatementHow to Read a Balance SheetHow to Read an Income Statement
Los datos se obtienen de la base de datos pública EDGAR SEC de EE. UU. Este sitio no proporciona asesoramiento de inversión.